Indivior Pharmaceuticals (INDV) Price to Earnings (2024 - 2026)

Indivior Pharmaceuticals has reported Price to Earnings for 3 years, with the latest figure at 39.69 in Q2 2026.

• On a quarterly basis, Price to Earnings fell 61.15% year-over-year to 39.69 in Q2 2026; TTM through Jun 2026 was 13.64, a 19.16% decrease from a year earlier, with the FY2025 full-year figure at 21.37, down 90.35% from the prior year.
• Price to Earnings was 39.69 for Q2 2026 at Indivior Pharmaceuticals, down from 41.75 in the prior quarter.
• The five-year high for Price to Earnings was 102.17 in Q2 2025, with the low at 22.21 in Q2 2024.
• Average Price to Earnings over 3 years is 48.11, with a median of 45.49 recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Price to Earnings jumped 560.11% in 2025, then slumped 61.15% in 2026.
• Over 3 years, Price to Earnings stood at 73.78 in 2024, then sank by 40.38% to 43.99 in 2025, then decreased by 9.78% to 39.69 in 2026.
• The last three Price to Earnings figures came in at 39.69 (Q2 2026), 41.75 (Q1 2026), and 43.99 (Q4 2025), per Business Quant data.